System (System Labs), a provider of online longevity and preventative care treatments and support, has raised $20 million in new funding from Patron Fund, Will Ventures, Vine, Courtside, Daybreak, SV Angel, and RiverPark Ventures.
The fresh funding comes as the global peptide therapeutics market is projected to reach $163 billion by 2026, according to data provided by System Labs.
“My vision was never to be another DTC telehealth brand, but to own more of the stack and build the foundation this category needs as it moves into the mainstream,” said Adam Steinle, Founder and CEO of System Labs.
“We want to be category definers and the solution Americans use and trust for their long-term health. This funding signals that we’re building a company that is filling the gap between concierge clinics and research-grade access that no single platform currently owns,” added Adam Steinle.
System Labs is a telehealth-powered peptide platform delivering science-backed, physician-guided treatments through licensed U.S. clinicians and certified American compounding pharmacies. Its peptide offerings include Glutathione, MIC+B12, NAD+, and Sermorelin to support energy, recovery, metabolism, muscle, skin, and healthy aging.
Digital health startups, including virtual care providers, have raised $200+ billion in VC funding to date, according to our latest Funding Database.
More recently, Wellinks, a provider of telehealth-enabled remote patient monitoring solutions, has raised $10 million in a Series B funding round led by UMass Memorial Health.
In another deal, Zócalo Health, a provider of AI-powered virtual primary care for Latino patients, has raised $15 million in Series A funding. Including the latest Series A round, Zócalo Health has raised $22.75 million in funding to date.